Abstracts

DOLUTEGRAVIR AS MAINTENANCE MONOTHERAPY FOR HIV-1: A RANDOMIZED CLINICAL TRIAL

The development of integrase (IN) inhibitor resistance during dolutegravir (DTG) containing cART is exceedingly rare. This high genetic resistance barrier may make DTG suitable as maintenance monotherapy. We hypothesized that DTG monotherapy is non-inferior to cART in maintaining viral suppression. Multicenter randomized trial comparing DTG 50mg QD (DOLUMONO) with continued cART(con-cART). Pts included were HIV-1+…

SIGNIFICANT EFFICACY & LONG-TERM SAFETY DIFFERENCE WITH TAF-BASED STR IN NAÏVE ADULTS

Two randomized, controlled, double-blinded multinational Phase 3 trials compared tenofovir alafenamide (TAF) vs tenofovir disoproxil fumarate (TDF), each in single-tablet regimens coformulated with elvitegravir/cobicistat/emtricitabine (E/C/F). At Week (W) 48, E/C/F/TAF was statistically noninferior to E/C/F/TDF for the proportion of subjects with HIV-1 RNA <50 copies(c)/mL and had significant improvements in renal and bone safety endpoints.…

PATTERNS OF EFAVIRENZ USE AS FIRST-LINE THERAPY IN THE UNITED STATES: 1999–2015

Between 1999 and 2014 efavirenz was recommended as first-line therapy for HIV-infected adults in the US, and continues to be recommended globally by the WHO. However, efavirenz has been linked to suicidal behavior and may not be appropriate for patients with mental illness. We examined the patterns of initiating efavirenz-containing first line combination antiretroviral therapy…

ART INITIATION, REGARDLESS OF COMPOSITION, IMPROVES PATIENT-REPORTED DEPRESSION

More than 50% of persons living with HIV (PLWH) have depression. Co-morbid HIV and depression yield reduced rates of antiretroviral therapy (ART) adherence and higher rates of HIV viral progression and mortality. We hypothesized that patient and ART-specific factors are associated with depression 12 months after ART initiation. This retrospective study included treatment-naïve PLWH initiating…

THE CLINICAL AND ECONOMIC IMPACT OF DOLUTEGRAVIR-BASED FIRST-LINE ART IN INDIA

Dolutegravir (DTG)-based antiretroviral therapy (ART) has proven superior or non-inferior to other regimens and is recommended first-line treatment in the US. Efavirenz (EFV)-based regimens remain the standard of care (SOC) in India and other resource-limited settings, where DTG is not yet available. Anticipating generic DTG availability, we examined the clinical outcomes, cost-effectiveness, and budgetary impact…

QUALITY OF LIFE IMPROVEMENT DURING SECOND-LINE THERAPY IN RESOURCE-LIMITED SETTINGS

Health-related quality of life (QoL) improves on first-line antiretroviral therapy (ART). However, at first-line failure, we have previously described poorer QoL among people in resource-limited settings (RLS) with higher viral load (VL). Change in QoL after starting second-line ART in RLS has not been evaluated. ACTG A5273 was a randomized clinical trial of second-line ART…

PROMISING RESULTS OF DOLUTEGRAVIR + LAMIVUDINE MAINTENANCE IN ANRS 167 LAMIDOL TRIAL

Dolutegravir (DTG) is a potent INSTI with high genetic barrier. The once-daily (QD) DTG-3TC combination is attractive, both drugs being safe, highly efficient and convenient. ANRS 167 LAMIDOL trial is an ongoing open-label, single-arm, multicenter trial assessing the efficacy and tolerance of DTG (50mgQD) – 3TC (300mgQD) in HIV-1 virologically suppressed patients (Pts) on first…

ADVERSE DRUG REACTIONS AMONG PATIENTS RECEIVING SECOND-LINE ART IN SOUTH AFRICA

As first-line antiretroviral therapy (ART) programmes mature, an increasing number of patients are being switched to second-line regimens. Adverse drug reactions (ADRs) which result primarily from medicines toxicity and drug interactions may compromise the effectiveness of treatment programs through its potential impact on treatment adherence and retention. Understanding the timing and rate of ADRs among…